Compare SMX Security Matters plc (SMX) vs TG Therapeutics Inc (TGTX) Price & Performance

SMX trades at $3.79, down 2.82% with bearish technical signals despite oversold RSI readings. The company shows severe financial distress with zero revenue, negative $169.18M net income, and negative ROE of -819.22%. Recent news highlights SMX's Digital Material Passport technology gaining media attention from Forbes, TIME, and Boston Herald for recycled plastic verification and 'Made in America' authentication solutions.

The outlook remains highly speculative given the absence of revenue and substantial losses. While technology innovation presents long-term potential, immediate risks include cash burn sustainability and dependence on financing activities. Investors should approach with caution given the fundamental weaknesses and bearish technical indicators.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.